Tesaro vet jumps to an Irish oncology upstart and shifts focus to the US, eyeing fundraising
Tim Pearson’s biotech break is over.
After picking up a $12 million payout late last year following the sale of Tesaro to GSK, the former Tesaro CFO’s next chapter in biotech will be written at another cancer company.
Pearson has been named CEO at Carrick Therapeutics, which picked up a $95 million round three years ago to bring in oncology drugs and grow a pipeline. Just 8 months ago the longtime dealmaker George Golumbeski joined the Dublin-based company — with operations in the UK as well — as chairman of the board. And now Golumbeski is installing Pearson as chief executive while company founder Elaine Sullivan transitions to a support role as adviser and “executive entrepreneur.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.